News Image

Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced.

By Mill Chart

Last update: Feb 28, 2024

Here's NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) for you, a growth stock our stock screener believes is undervalued. NASDAQ:NBIX is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced. Let's break it down further.

Exploring NASDAQ:NBIX's Growth

To evaluate a stock's growth potential, ChartMill utilizes a Growth Rating on a scale of 0 to 10. This comprehensive assessment considers various growth aspects, including historical and estimated EPS and revenue growth. NASDAQ:NBIX has achieved a 9 out of 10:

  • The Earnings Per Share has grown by an impressive 58.17% over the past year.
  • NBIX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 70.09% yearly.
  • The Revenue has grown by 26.76% in the past year. This is a very strong growth!
  • The Revenue has been growing by 33.13% on average over the past years. This is a very strong growth!
  • The Earnings Per Share is expected to grow by 42.64% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 13.87% on average over the next years. This is quite good.

Assessing Valuation Metrics for NASDAQ:NBIX

ChartMill assigns a Valuation Rating to each stock, ranging from 0 to 10. This rating is calculated by analyzing different valuation elements, such as price to earnings and free cash flow, both in absolute terms and relative to the market and industry. In the case of NASDAQ:NBIX, the assigned 7 reflects its valuation:

  • 94.75% of the companies in the same industry are more expensive than NBIX, based on the Price/Earnings ratio.
  • Based on the Price/Forward Earnings ratio, NBIX is valued cheaper than 95.42% of the companies in the same industry.
  • NBIX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. NBIX is cheaper than 94.75% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, NBIX is valued cheaply inside the industry as 95.59% of the companies are valued more expensively.
  • NBIX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • NBIX has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as NBIX's earnings are expected to grow with 62.72% in the coming years.

A Closer Look at Health for NASDAQ:NBIX

ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NASDAQ:NBIX, the assigned 7 for health provides valuable insights:

  • An Altman-Z score of 9.13 indicates that NBIX is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of NBIX (9.13) is better than 82.88% of its industry peers.
  • NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
  • A Current Ratio of 2.45 indicates that NBIX has no problem at all paying its short term obligations.
  • A Quick Ratio of 2.40 indicates that NBIX has no problem at all paying its short term obligations.

Assessing Profitability for NASDAQ:NBIX

ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NASDAQ:NBIX scores a 9 out of 10:

  • The Return On Assets of NBIX (7.68%) is better than 96.61% of its industry peers.
  • The Return On Equity of NBIX (11.19%) is better than 96.27% of its industry peers.
  • NBIX has a better Return On Invested Capital (11.21%) than 96.78% of its industry peers.
  • The 3 year average ROIC (9.89%) for NBIX is below the current ROIC(11.21%), indicating increased profibility in the last year.
  • NBIX's Profit Margin of 13.23% is amongst the best of the industry. NBIX outperforms 96.61% of its industry peers.
  • In the last couple of years the Profit Margin of NBIX has grown nicely.
  • NBIX's Operating Margin of 20.92% is amongst the best of the industry. NBIX outperforms 97.12% of its industry peers.
  • In the last couple of years the Operating Margin of NBIX has grown nicely.
  • NBIX has a better Gross Margin (97.90%) than 97.63% of its industry peers.

Our Affordable Growth screener lists more Affordable Growth stocks and is updated daily.

For an up to date full fundamental analysis you can check the fundamental report of NBIX

Keep in mind

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

NEUROCRINE BIOSCIENCES INC

NASDAQ:NBIX (5/17/2024, 7:15:36 PM)

After market: 142.29 0 (0%)

142.29

+0.38 (+0.27%)

NBIX News

News Imagea day ago - Market News VideoInteresting NBIX Put And Call Options For July 19th
News Image2 days ago - Market News VideoNeurocrine Biosciences Moves Up In Market Cap Rank, Passing Pool
News Image4 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024

- CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitations of Current CAH Treatment Paradigm in Children, Adolescents and Adults - Phase 2 Study for...

News Image9 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present CAHtalyst™ Adult Phase 3 clinical study baseline...

News Image9 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety,...

News Image10 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the...

News Image11 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the BofA Securities 2024 Health Care Conference at 11:20 a.m. Pacific Time (2:20...

News Image12 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today renewed its commitment to increasing awareness and advancing care for people living with TD...

News Image14 days ago - Investor's Business DailyNvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam

The market rally appears to be picking up steam.

News Image15 days ago - Investor's Business DailyA Week Of Fast-Moving Stocks Ahead: Disney, Toyota, Ferrari, Constellation

Earnings season moves into final innings, some fast-moving names led by Disney, Ferrari and Constellation report.

News Image15 days ago - Investor's Business DailyStock Market Rallies On Fed, Jobs Report, Apple: Weekly Review

The Nasdaq regained its 50-day line Friday. The other indexes hit resistance.

News Image15 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today presented the CAHtalyst™ Pediatric Phase 3 clinical study baseline characteristics data for...

NBIX Links
Follow us for more